<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82098">
  <stage>Registered</stage>
  <submitdate>17/06/2007</submitdate>
  <approvaldate>14/03/2008</approvaldate>
  <actrnumber>ACTRN12608000132347</actrnumber>
  <trial_identification>
    <studytitle>Effects of a herbal preparation containing Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneolum Syntheticum on circulating adhesion molecules and cardiovascular risk</studytitle>
    <scientifictitle>Effects of a herbal preparation containing Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneolum Syntheticum on circulating adhesion molecules and cardiovascular risk</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cardiovascular risk</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Chinese herbal medicine treatment: combination of three Chinese herbs (Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneolum Syntheticum) in capsule form, oral administration, 1 packet of capsules three times/day for 12 weeks.</interventions>
    <comparator>Matched placebo control in capsule form (polyethylene glycol 6000 [PEG 6000] plus caramel), oral administration, 1 packet of capsules three times/day for 12 weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adhesion molecule expression</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular risk</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy individuals aged 18 years and over with a total plasma cholesterol of 5.0 mmol/L or above, triglyceride level of greater than 2 mmol/L or high density lipoprotein (HDL) cholesterol level of less than 1.0 mmol/L.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria included plasma triglyceride levels over 10 mmol/L, established heart disease, other serious medical or psychological conditions, pregnancy, current use of vasoactive medications, warfarin, and postmenopausal hormone therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Study medications coded and labelled numerically.  Computerised random number code generated, boxes of study medications labelled accordingly. Patients allocated study medications in numberical sequence in order of enrolment into study.</concealment>
    <sequence>Computerised random number generator</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/10/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3000</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Monash University</primarysponsorname>
    <primarysponsoraddress>Alfred Lane
Prahran VIC 3181</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Tianjin Tasly Pharmaceutical Co Ltd</fundingname>
      <fundingaddress>1 Liaohe East Rd and New Yibai St
Tianjin 300402</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australia-China Fund Grant</fundingname>
      <fundingaddress>Commonwealth Department of Education, Science and Training
Canberra ACT</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A parallel double blind randomised placebo-controlled study was conducted to assess the effects of a Chinese herbal medicine, the Dantonic Pill, on circulating adhesion molecules in participants with mild-moderate hypercholesterolemia.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>Alfred Hospital
Commercial Rd
Prahran VIC 3181</ethicaddress>
      <ethicapprovaldate>6/01/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash University Ethics Committee</ethicname>
      <ethicaddress>Monash University
Clayton Rd
Clayton VIC 3168</ethicaddress>
      <ethicapprovaldate>16/09/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Paul Komesaroff</name>
      <address>Monash University
Department of Medicine
Alfred Hospital
Commercial Rd
Prahran VIC 3181</address>
      <phone>+61 3 99030622</phone>
      <fax />
      <email>paul.komesaroff@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Paul Komesaroff</name>
      <address>Monash University
Department of Medicine
Alfred Hospital
Commercial Rd
Prahran VIC 3181</address>
      <phone>+61 3 99030622</phone>
      <fax />
      <email>paul.komesaroff@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Kylie O'Brien</name>
      <address>Department of Health, Engineering and Science
Victoria University
PO Box 14428
Melbourne VIC 8001</address>
      <phone>+61 3 99192792</phone>
      <fax />
      <email>kylie.obrien@vu.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>